×
Please click
here
if you are not redirected within a few seconds.
All
News
Videos
Images
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Cassava Sciences (SAVA) Jumps: Stock Rises 9.2%
Yahoo News New Zealand
Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
7 hours ago
Is There Any Hope for Cassava Sciences Stock?
The Motley Fool
Key Points. Cassava Sciences stock is down due to questions about some of its research. A lot is riding on its late-stage clinical trials to...
3 months ago
Cassava Sciences' Alzheimer's clinical trials should be halted
STAT
It's time for the FDA to halt Cassava Sciences' Alzheimer's clinical trials ... The Food and Drug Administration should halt Cassava Sciences'...
6 months ago
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
GlobeNewswire
AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA) (“Cassava Sciences” or the "Company") has been advised...
1 day ago
Co-developer of Cassava's potential Alzheimer's drug cited for 'egregious misconduct'
Science | AAAS
Cassava Sciences, a biotech company whose work on the experimental Alzheimer's drug simufilam has been heavily criticized and is the subject...
6 months ago
Cassava Sciences: New Year, Same Game Of Smoke And Mirrors (NASDAQ:SAVA)
Seeking Alpha
Cassava Sciences reported 2023 cash of $121.1m, $(97.2m) of net loss and R&D expenses increased to $89.4m. Read more on SAVA stock here.
1 month ago
Scientists Investigating Alzheimer's Drug Faulted in Leaked Report
The New York Times
A professor at the City College of New York engaged in “significant research misconduct,” an expert committee concluded.
6 months ago
Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks
InvestorPlace
As the stock market corrects, focusing on stable investments is crucial. This is why you should steer clear of these biotech stocks to...
2 days ago
Topline results of Phase 3 studies of simufilam for Alzheimer's...
Alzheimer's News Today
A total of 1929 Alzheimer's patients have enrolled in two simufilam studies, which the FDA said could support its application for approval.
2 months ago
Cassava Sciences Adviser Found to Have Committed 'Egregious Misconduct'
WSJ
The university investigation also found “evidence highly suggestive of deliberate scientific misconduct” by Hoau-Yan Wang, a medical professor...
6 months ago